What Is a Stapled Peptide? Definition and What Research Reports

Definition

A stapled peptide is a synthetic peptide in which two amino acid side chains have been chemically joined by a covalent cross-link — the "staple" — so that the peptide backbone is held in a fixed conformation, usually an alpha-helix. The staple is installed during or after solid-phase synthesis, most commonly as a hydrocarbon bridge formed by ring-closing metathesis between two non-natural olefin-bearing residues, though biaryl and other linker chemistries are also used, as in the biaryl-stapled GLP-1R/GIPR dual agonists described by researchers in a 2022 report (PMID 35417146). "Stapled peptide" therefore names a design strategy and a structural class — not a single molecule, a single target, or a product.

What class of molecule it is, and where it comes from

Stapled peptides sit between conventional peptides and small molecules. They are typically short — often on the order of a helical turn or a few turns — and are made in the laboratory rather than isolated from tissue. The parent sequence is usually borrowed from a natural protein: the helical segment of a protein that docks into a partner protein's binding groove. Chemists then substitute two positions on the same face of that helix with residues that can be tied together, and close the staple.

The rationale, as it appears throughout the literature, is that short peptides taken out of their parent protein lose their folded shape in solution, bind weakly, and are cleaved quickly by proteases. Locking the helix is intended to restore the bound-state geometry before the peptide ever meets its target. Stability is an explicit design goal in this field: the 2022 ACS Chemical Biology study described its biaryl-stapled peptides as both potent and proteolytically stable GLP-1R/GIPR dual agonists (PMID 35417146).

Common vocabulary around the term

• Hydrocarbon-stapled — the most frequently reported staple chemistry, used in the paxillin peptides reported to block FAK scaffolding in cancer models (PMID 40021642).
• Biaryl-stapled — an aromatic cross-link, used in the GLP-1R/GIPR dual agonist series (PMID 35417146).
• Switchable staple — a linker whose geometry can be changed by an external trigger; a 2016 Journal of Peptide Science paper was titled simply "A switchable stapled peptide" (PMID 26785930).
• Stapled-peptide PROTAC — a stapled binder fused to an E3-ligase recruiter, described for MDM2/MDMX degradation (PMID 36185610).
• Conjugated stapled peptide — a staple combined with a delivery element, such as the penetratin-conjugated stapled peptide reported against Wnt/β-catenin signalling (PMID 36198218).

How the term is used in peptide research

In practice, researchers use "stapled peptide" the way they use "macrocycle" or "peptidomimetic": as shorthand for a chemically constrained binder aimed at a target that conventional small molecules struggle with. The classic use case is a protein–protein interaction — a flat, extended interface with no deep pocket. Because one side of a helix can bury a large surface, a stapled helix is the geometry chemists reach for first.

The term also appears in delivery and imaging contexts, where the staple is not the pharmacophore but part of the vehicle. A 2020 Nanomaterials report described hydrocarbon-stapled peptide-based nanoparticles assembled for siRNA delivery (PMID 33255624), and a 2025 Journal of Medicinal Chemistry study described ⁶⁴Cu-labelled stapled-peptide radiopharmaceuticals directed at MDM2/MDMX for pan-p53 tumour imaging (PMID 41138151).

What the Published Literature Reports

The published record on stapled peptides is dominated by chemistry, structural biology, cell-based assays and animal models. Across the verified papers below, the study designs are preclinical: synthesis and characterisation, target-engagement assays, cell work, and in some cases rodent experiments.

On targets that had resisted small molecules, researchers reported a SOS1-inspired hydrocarbon-stapled peptide acting as a pan-Ras inhibitor in a 2023 Bioorganic Chemistry paper (PMID 37003134), and a 2025 Nature Communications study reported structure-based discovery of hydrocarbon-stapled paxillin peptides that blocked FAK scaffolding in cancer (PMID 40021642). A 2020 ChemBioChem report described stapled peptide inhibitors of the autophagy adapter LC3B (PMID 32406996), and a 2022 Bioorganic & Medicinal Chemistry paper described a penetratin-conjugated stapled peptide that inhibited Wnt/β-catenin signalling (PMID 36198218).

Beyond oncology-adjacent targets, a 2023 Frontiers in Cardiovascular Medicine study reported that short hydrocarbon-stapled ApoC2-mimetic peptides activated lipoprotein lipase and lowered plasma triglycerides in mice (PMID 37547254), and a 2026 European Journal of Medicinal Chemistry paper reported stapled peptide inhibitors of VGLL4/TEAD4 interactions that accelerated cutaneous wound healing in its models (PMID 41478010). Two separate groups extended the format into targeted degradation, reporting stapled peptide-based PROTACs designed for atypical MDM2/MDMX degradation and tumour suppression in 2022 (PMID 36185610) and a further MDM2/MDMX stapled-peptide PROTAC design, synthesis and activity study in 2025 (PMID 40999047).

Representative research applications

Safety and Tolerability: What Studies Report

The verified papers summarised here are chemistry and preclinical pharmacology reports; they characterise synthesis, binding, cell activity and, in some cases, rodent outcomes rather than human tolerability. The 2023 ApoC2-mimetic work, for example, reported triglyceride lowering in mice rather than in people (PMID 37547254), and the 2026 VGLL4/TEAD4 work reported wound-healing effects in its experimental models (PMID 41478010). No human adverse-event profile for stapled peptides as a class can be drawn from these sources, and none of them is presented here as a basis for use. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any decision involving an investigational compound.

How the term differs from neighbouring terms

• Stapled peptide vs. cyclic peptide — both are constrained, but a staple specifically bridges two side chains to hold a secondary structure, classically a helix, while "cyclic" usually describes head-to-tail or backbone closure.
• Stapled peptide vs. peptidomimetic — peptidomimetic is the broader umbrella; stapled peptides are one subclass within it.
• Stapled peptide vs. peptide conjugate — a conjugate adds a separate functional module, as with the penetratin-conjugated stapled peptide reported against Wnt/β-catenin signalling (PMID 36198218); the two ideas are often combined.

Regulatory status of the term

"Stapled peptide" is a chemical descriptor, not a regulatory category. The compounds described in the literature above are research materials studied in laboratory and animal settings; a stapled peptide is not an approved drug by virtue of being stapled, and each molecule carries its own individual status.

References

• Hydrocarbon-Stapled Peptide Based-Nanoparticles for siRNA Delivery (Nanomaterials, 2020)
• (64)Cu-Labeled Stapled Peptide-Based Radiopharmaceuticals Targeting MDM2/MDMX for Pan-p53 Tumors (Journal of Medicinal Chemistry, 2025)
• Structure-based discovery of hydrocarbon-stapled paxillin peptides that block FAK scaffolding in cancer (Nature Communications, 2025)
• Stapled peptide inhibitors target VGLL4/TEAD4 interactions to accelerate cutaneous wound healing (European Journal of Medicinal Chemistry, 2026)
• Short hydrocarbon stapled ApoC2-mimetic peptides activate lipoprotein lipase and lower plasma triglycerides in mice (Frontiers in Cardiovascular Medicine, 2023)
• SOS1-inspired hydrocarbon-stapled peptide as a pan-Ras inhibitor (Bioorganic Chemistry, 2023)
• Stapled Peptide Inhibitors of Autophagy Adapter LC3B (ChemBioChem, 2020)
• Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists (ACS Chemical Biology, 2022)
• Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression (Theranostics, 2022)
• Study on the design, synthesis and activity of MDM2/MDMX anti-tumor stapled peptide PROTAC (Scientific Reports, 2025)
• Development of a penetratin-conjugated stapled peptide that inhibits Wnt/β-catenin signaling (Bioorganic & Medicinal Chemistry, 2022)
• A switchable stapled peptide (Journal of Peptide Science, 2016)